PetVivo Hldgs Valuation Multiples

Discover PetVivo Hldgs' revenue and EBITDA valuation multiples and M&A history.

PetVivo Hldgs Overview

About PetVivo Hldgs

PetVivo Holdings Inc is an emerging biomedical device company. It is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for companion animals. The product pipeline includes approximately seventeen products intended to treat animals and people. Its patent protection extends to biomaterials, products, production processes, and methods of use provided by the company's portfolio of several patents. The company has also begun the commercialization of its product Spryng with OsteoCushion technology, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions such as osteoarthritis in dogs and horses.


Founded

2009

HQ

United States

Employees

24

Financials (FY)

Revenue: $1M
EBITDA: ($9M)

EV

$31M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

PetVivo Hldgs Financials

PetVivo Hldgs reported last fiscal year revenue of $1M and negative EBITDA of ($9M).

In the same fiscal year, PetVivo Hldgs generated $755K in gross profit, ($9M) in EBITDA losses, and had net loss of ($10M).


PetVivo Hldgs P&L

In the most recent fiscal year, PetVivo Hldgs reported revenue of $1M and EBITDA of ($9M).

PetVivo Hldgs is unprofitable as of last fiscal year, with gross margin of 66%, EBITDA margin of (777%), and net margin of (917%).

See analyst estimates for PetVivo Hldgs
Last FY202320242025202620272028
Revenue$1M$956K$1M$1M
Gross Profit$755K$652K$931K$815K
Gross Margin66%68%85%72%
EBITDA($9M)($10M)($8M)($9M)
EBITDA Margin(777%)(1049%)(768%)(752%)
EBIT Margin(706%)(1062%)(797%)(708%)
Net Profit($10M)($10M)($9M)($10M)
Net Margin(917%)(1088%)(828%)(874%)
Net Debt$121K---

Financial data powered by Morningstar, Inc.

PetVivo Hldgs Stock Performance

PetVivo Hldgs has current market cap of $31M, and enterprise value of $31M.


PetVivo Hldgs' stock price is $0.82.

PetVivo Hldgs has an EPS (earnings per share) of $-0.28.

See more trading valuation data for PetVivo Hldgs
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$31M$31M0.0%---$-0.28

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

PetVivo Hldgs Valuation Multiples

PetVivo Hldgs trades at 27.0x EV/Revenue multiple, and (3.5x) EV/EBITDA.

See NTM and 2027E valuation multiples for PetVivo Hldgs

PetVivo Hldgs Financial Valuation Multiples

As of July 9, 2026, PetVivo Hldgs has market cap of $31M and EV of $31M.

PetVivo Hldgs has a P/E ratio of (2.9x).

Last FY202320242025202620272028
EV/Revenue27.0x32.2x28.2x27.1x
EV/EBITDA(3.5x)(3.1x)(3.7x)(3.6x)
EV/EBIT(3.8x)(3.0x)(3.5x)(3.8x)
EV/Gross Profit40.8x47.3x33.1x37.8x
P/E(2.9x)(3.0x)(3.4x)(3.1x)
EV/FCF(5.0x)(4.1x)(4.9x)(5.1x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified PetVivo Hldgs Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

PetVivo Hldgs Margins & Growth Rates

In the most recent fiscal year, PetVivo Hldgs reported gross margin of 66%, EBITDA margin of (777%), and net margin of (917%).

See estimated margins and future growth rates for PetVivo Hldgs

PetVivo Hldgs Margins

Last FY202420252026202720282029
Gross Margin66%85%72%66%
EBITDA Margin(777%)(768%)(752%)(777%)
EBIT Margin(706%)(797%)(708%)(706%)
Net Margin(917%)(828%)(874%)(917%)
FCF Margin(536%)(581%)(532%)(536%)

PetVivo Hldgs Growth Rates

23/2424/2525/2626/2727/2828/29
Revenue Growth14%4%0%
Gross Profit Growth43%(12%)(7%)
EBITDA Growth(16%)2%3%
EBIT Growth(14%)(7%)0%
Net Profit Growth(13%)10%5%
FCF Growth(17%)(5%)1%

Data powered by FactSet, Inc. and Morningstar, Inc.

PetVivo Hldgs Operational KPIs

PetVivo Hldgs' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.4M for the same period.

PetVivo Hldgs' Rule of 40 is (776%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

PetVivo Hldgs' Rule of X is (776%) (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for PetVivo Hldgs
Last FY202320242025202620272028
Rule of 40(776%)---
Bessemer Rule of X(776%)---
Revenue per Employee$0.0M---
Opex per Employee$0.4M---
S&M Expenses to Revenue269%356%260%260%
G&A Expenses to Revenue380%657%485%391%
R&D Expenses to Revenue124%118%138%128%
Opex to Revenue772%1130%882%779%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

PetVivo Hldgs Competitors

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E

This data is available for Pro users. Sign up to see all PetVivo Hldgs competitors and their valuation data.

Start Free Trial

Acquisitions by PetVivo Hldgs

PetVivo Hldgs has acquired 2 companies to date.

Last acquisition by PetVivo Hldgs was on June 23rd 2026. PetVivo Hldgs acquired PiezoBioMembrane for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by PetVivo Hldgs

PiezoBioMembrane
Gel-Del Technologies
Description
PiezoBioMembrane is a materials developer. It produces biodegradable substances that exhibit piezoelectric characteristics for applications inside medical implants.
Gel-Del Technologies develops protein-based thermoplastic biomaterials for biomedical devices including dermal fillers, vascular grafts, and drug delivery systems. Its CosmetaLife particles completed an FDA-approved trial outperforming Restylane in wrinkle reduction over 12 months, with applications tested in animal models for orthopedics and cardiology.
HQ CountryUnited StatesUnited States
HQ City
Hartford, CT
Minnesota City, MN
Deal Date23 Jun 20262 Jun 2014
Valuationundisclosed$40M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all PetVivo Hldgs acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About PetVivo Hldgs

When was PetVivo Hldgs founded?PetVivo Hldgs was founded in 2009.
Where is PetVivo Hldgs headquartered?PetVivo Hldgs is headquartered in United States.
How many employees does PetVivo Hldgs have?As of today, PetVivo Hldgs has over 24 employees.
Is PetVivo Hldgs publicly listed?Yes, PetVivo Hldgs is a public company listed on OTCM.
What is the stock symbol of PetVivo Hldgs?PetVivo Hldgs trades under PETV ticker.
When did PetVivo Hldgs go public?PetVivo Hldgs went public in 2012.
Who are competitors of PetVivo Hldgs?PetVivo Hldgs main competitors include
What is the current market cap of PetVivo Hldgs?PetVivo Hldgs' current market cap is $31M.
What is the current revenue of PetVivo Hldgs?PetVivo Hldgs' last fiscal year revenue is $1M.
What is the current EV/Revenue multiple of PetVivo Hldgs?Current revenue multiple of PetVivo Hldgs is 27.0x.
Is PetVivo Hldgs profitable?No, PetVivo Hldgs is not profitable.
How many companies PetVivo Hldgs has acquired to date?As of July 2026, PetVivo Hldgs has acquired 2 companies.
In how many companies PetVivo Hldgs has invested to date?PetVivo Hldgs hasn't invested in any companies yet (or none have been disclosed publicly).

Lists including PetVivo Hldgs

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial